Intravenous human polyclonal anti-HBs IgG (brand: Hepatect CP) used as passive immunotherapy before liver resection or transplant; neutralizes HBV virions and HBsAg subviral particles to lower HBsAg, can be internalized by hepatocytes to inhibit HBsAg/virion secretion, and mediates Fc-dependent ADCC against HBV-infected hepatocytes; preclinical data suggest direct anti-tumor effects on HBV-related HCC tumor-initiating cells.